Twist Bioscience revenue and financials
$169.64Change from previous close: −17.25%Absolute change: −$35.36
In the fiscal year ended September 2025, Twist Bioscience reported revenue of $376.57M (+20.32% year over year). The net loss was $77.67M.
Fiscal year ending in September. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +20.32%
- FY to Sep 2025 vs FY to Sep 2024
- Net margin
- -20.6%
- FY to Sep 2024: -66.7%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | FY to Sep 2025 | FY to Sep 2024 | FY to Sep 2023 | FY to Sep 2022 | FY to Sep 2021 | FY to Sep 2020 | FY to Sep 2019 | FY to Sep 2018 | FY to Sep 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -47.6 | -64.1 | -142 | -124 | -112 | -142 | -87.9 | -66.2 | -51.3 |
| Depreciation and amortization | 24.9 | 31.4 | 29.3 | 16.5 | 9.8 | 6.7 | 6.1 | 5.7 | 5.0 |
| Capital expenditure | -28.0 | -5.1 | -27.8 | -102 | -27.1 | -9.9 | -14.8 | -3.7 | -6.6 |
| Investing cash flow | -24.8 | -3.1 | 50.6 | -233 | 156 | — | — | — | — |
| Financing cash flow | 28.5 | 6.9 | 0.9 | 271 | 329 | — | — | — | — |
| Share repurchases | -0.0 | -4.0 | -4.4 | -7.8 | -10.8 | — | — | — | — |
| Debt repaid | — | 0.0 | 0.0 | -1.6 | — | — | — | — | — |
| Effect of exchange rates | 0.1 | 0.1 | -0.0 | -0.3 | 0.0 | — | — | — | — |
| Net change in cash | -43.7 | -60.1 | -91.0 | -87.1 | 373 | — | — | — | — |
| Free cash flow | -75.6 | -69.2 | -170 | -226 | -139 | — | — | — | — |
| Levered free cash flow | -32.6 | -17.4 | -112 | -161 | -73.1 | — | — | — | — |